ACE-inhibitors, beta-blockers or the combination in heart failure: Is it just an A-B-C ? Editorial to: Effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.

Cardiovascular Drugs and Therapy

Volumn 22, Issue 4, 2008, Pages 261-263

  De Boer, Rudolf A ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARBAZOLES; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART FAILURE, SYSTOLIC; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROPANOLAMINES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 48349114995     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6107-x     Document Type: Editorial

References (19)

1. LB Daniels AS Maisel 2007 Natriuretic peptides J Am Coll Cardiol 50 2357 68
2. G Tjeerdsma RA de Boer F Boomsma MP van den Berg YM Pinto DJ van Veldhuisen 2002 Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure Int J Cardiol 86 143 9
3. RA de Boer RH Henning AJ Suurmeijer YM Pinto E Olthof JH Kirkels WH van Gilst HJ Crijns DJ van Veldhuisen 2001 Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease Int J Cardiol 78 5 12
4. M Suo N Hautala G Földes I Szokodi M Tóth H Leskinen P Uusimaa O Vuolteenaho M Nemer H Ruskoaho 2002 Posttranscriptional control of BNP gene expression in angiotensin II-induced hypertension Hypertension 39 803 8
5. T Majalahti M Suo-Palosaari B Sármán N Hautala S Pikkarainen H Tokola O Vuolteenaho J Wang P Paradis M Nemer H Ruskoaho 2007 Cardiac BNP gene activation by angiotensin II in vivo Mol Cell Endocrinol 273 59 67
6. SS Bhalla L Robitaille M Nemer 2001 Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter J Biol Chem 276 11439 45
7. M Marttila N Hautala P Paradis M Toth O Vuolteenaho M Nemer H Ruskoaho 2001 GATA4 mediates activation of the B-type natriuretic peptide gene expression in response to hemodynamic stress Endocrinology 142 4693 700
8. M White S Lepage J Lavoie S De Denus MH Leblanc D Gossard L Whittom N Racine A Ducharme F Dabouz JL Rouleau R Touyz 2007 Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure J Card Fail 13 86 94
9. Q He M Mendez MC LaPointe 2002 Regulation of the human brain natriuretic peptide gene by GATA-4 Am J Physiol Endocrinol Metab 283 E50 7
10. ME Davis AM Richards MG Nicholls TG Yandle CM Frampton RW Troughton 2006 Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure Circulation 113 977 85
11. JE Sanderson WW Chan YT Hung SK Chan IO Shum K Raymond KS Woo 1995 Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker Br Heart J 74 502 7
12. Rosenberg J, Gustafsson F, Remme WJ, Riegger GAJ, Hildebrandt PR. The prognostic value of B-type natriuretic peptides during beta-blocker therapy in stable patients with systolic heart failure. Cardiovasc Drugs Ther 2008 (this issue).
13. DJ van Veldhuisen S Genth-Zotz J Brouwer F Boomsma T Netzer AJ Man In'T Veld YM Pinto KI Lie HJ Crijns 1998 High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril J Am Coll Cardiol 32 1811 8
14. WJ Remme 2003 Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN Study Cardiovasc Drugs Ther 17 107 9
15. RA de Boer DJ van Veldhuisen 2002 Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs Eur Heart J Suppl 4 D D111 6
16. M Komajda P Lapuerta N Hermans JR Gonzalez-Juanatey DJ van Veldhuisen E Erdmann L Tavazzi P Poole-Wilson C Le Pen 2005 Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey Eur Heart J 26 1653 9
17. WJ Remme G Riegger P Hildebrandt M Komajda W Jaarsma M Bobbio J Soler-Soler A Scherhag B Lutiger L Rydén 2004 The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN) Cardiovasc Drugs Ther 18 57 66
18. K Sliwa GR Norton N Kone G Candy J Kachope AJ Woodiwiss C Libhaber P Sareli R Essop 2004 Impact of initiating carvedilol before angiotensin- converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure J Am Coll Cardiol 44 1825 30
19. R Willenheimer DJ van Veldhuisen B Silke E Erdmann F Follath H Krum P Ponikowski A Skene L van de Ven P Verkenne P Lechat CIBIS III Investigators 2005 Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation 112 2426 35